Newsletters

10.23.24

Strategies for Meeting Patient Expectations and Improving Patient Experience During Cancer Treatment

Scientific advances have led to a significant reduction in cancer mortality and increased survival rates,  yet the number of annual cancer diagnoses continues to grow, with over two million new diagnoses expected in 2024.


05.23.24

Achieving a High Performance, Diverse Accrual, Clinical Trial Program in an Academic Health System

The United States occupies a leadership position in clinical advancements, in terms of pharmaceuticals, medical devices, innovative care processes and interventional techniques.


12.12.23

Trials & Tribulations: Removing Barriers to Participation in Clinical Trials to Advance Innovation

Through clinical trials, eligible patients can receive the latest cutting-edge treatments, which may not yet be available nationwide.


10.30.23

Achieving Clinical Trial Diversity: Expanding Hospital Capacity to Offer Trials in the Community

The inclusion of racial and ethnic groups in clinical trials has been a national priority for decades, but progress toward that end has been limited.


10.24.23

The Real Challenges That Stop Hospitals From Integrating Clinical Trials Into Clinical Care

A clinical trial infrastructure is often viewed as a cost rather than as a strategic investment. In any setting, to accrue more patients, organizations need a supporting and efficient infrastructure as well as a clinical practice culture that embraces research as part of their care delivery model.


11.02.22

Positioning for Value-Based Cancer Care: Lessons and Opportunities

The past 20 years have brought tremendous progress in cancer outcomes with improved screening and new treatments, such as immunotherapy, but with these innovations and our country’s aging population, escalating care costs and quality variation continue to confound the system.